Tauri Group chosen as JPEO-CBD prime contractor
The cumulative total to be awarded across all fields for those selected could be as high as $495 million over the next three years. The Tauri Group was selected as a prime contractor for the medical domain.
"The Tauri Group is known for its expertise in mitigating the effects of biological threats and we are thrilled to have been selected as a prime contractor for the JPEO-CBD OPETS Medical Domain," Cos DiMaggio, the firm's managing partner, said.
The Tauri Group was selected to provide technical know-how in microbiology, molecular biology, chemistry, biosurveillance and engineering. In addition, the group has relevant experience in program management and navigating the U.S. Department of Defense acquisition process and the U.S. Food and Drug Administration regulatory process for the development of medical countermeasures.
"The Tauri team is prepared to hit the ground running to assist JPEO-CBD in developing and fielding medical countermeasures," Ben Hagar, the Tauri Group's program manager, said. "Our involvement with DoD's Transformational Medical Technologies program is longstanding, and we are excited about the opportunity to extend our support across the broader medical domain."